Oxybuprocaine: Difference between revisions

	WikiDoc Resources for Oxybuprocaine
Articles
Most recent articles on Oxybuprocaine Most cited articles on Oxybuprocaine Review articles on Oxybuprocaine Articles on Oxybuprocaine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxybuprocaine Images of Oxybuprocaine Photos of Oxybuprocaine Podcasts & MP3s on Oxybuprocaine Videos on Oxybuprocaine
Evidence Based Medicine
Cochrane Collaboration on Oxybuprocaine Bandolier on Oxybuprocaine TRIP on Oxybuprocaine
Clinical Trials
Ongoing Trials on Oxybuprocaine at Clinical Trials.gov Trial results on Oxybuprocaine Clinical Trials on Oxybuprocaine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxybuprocaine NICE Guidance on Oxybuprocaine NHS PRODIGY Guidance FDA on Oxybuprocaine CDC on Oxybuprocaine
Books
Books on Oxybuprocaine
News
Oxybuprocaine in the news Be alerted to news on Oxybuprocaine News trends on Oxybuprocaine
Commentary
Blogs on Oxybuprocaine
Definitions
Definitions of Oxybuprocaine
Patient Resources / Community
Patient resources on Oxybuprocaine Discussion groups on Oxybuprocaine Patient Handouts on Oxybuprocaine Directions to Hospitals Treating Oxybuprocaine Risk calculators and risk factors for Oxybuprocaine
Healthcare Provider Resources
Symptoms of Oxybuprocaine Causes & Risk Factors for Oxybuprocaine Diagnostic studies for Oxybuprocaine Treatment of Oxybuprocaine
Continuing Medical Education (CME)
CME Programs on Oxybuprocaine
International
Oxybuprocaine en Espanol Oxybuprocaine en Francais
Business
Oxybuprocaine in the Marketplace Patents on Oxybuprocaine
Experimental / Informatics
List of terms related to Oxybuprocaine

Oxybuprocaine
Clinical data
Trade names	Novesin(e)
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: D ; ;
Routes of; administration	Topical
ATC code	D04AB03 (WHO) S01HA02 (WHO);
Pharmacokinetic data
Metabolism	Esterases in blood plasma and liver
Identifiers
	IUPAC name 2-diethylaminoethyl 4-amino-3-butoxy-benzoate;
CAS Number	99-43-4 ;
PubChem CID	4633;
DrugBank	DB00892 ;
ChemSpider	4472 ;
UNII	AXQ0JYM303;
KEGG	D08319 ;
ChEBI	CHEBI:309594 ;
ChEMBL	ChEMBL1200 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C17H28N2O3
Molar mass	308.41 g/mol
3D model (JSmol)	Interactive image;
	SMILES O=C(OCCN(CC)CC)c1cc(OCCCC)c(cc1)N;
	InChI InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3 ; Key:CMHHMUWAYWTMGS-UHFFFAOYSA-N ;
(verify)

← Older edit

VisualWikitext

Latest revision as of 15:27, 13 April 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxybuprocaine (INN), also known as benoxinate or BNX, is an ester-type local anesthetic, which is used especially in ophthalmology and otolaryngology. Oxybuprocaine is sold by Novartis under the brand names Novesine or Novesin.

Safety for use in pregnancy and lactation has not been established.

Uses

In ophthalmology in order to numb the surface of the eye (the outermost layers of the cornea and conjunctiva) for the following purposes:^[1]
- in order to perform a contact/applanation tonometry,
- for small operations,
- in order to remove small foreign objects from the uppermost layer of the cornea or conjunctiva;
in otolaryngology for numbing the mucous membranes of the nostrils and pharynx, for diagnostic purposes and small operations,^[2]
for numbing the mucous membranes of bronchi, for example in bronchoscopy,^[2]
and the oesophagus, for example in intubation.^[2]

Pharmacokinetics

Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on perfusion. The drug is metabolised by esterases in blood plasma and liver.^[2]

Adverse effects

When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example tetracaine, proxymetacaine and proparacaine) can cause irritation, hypersensitivity, anaphylaxis, irreversible corneal damage and even complete destruction of the cornea.^[1]^[3] (Excessive use means several times a day during several days or even weeks.)

Interactions

Oxybuprocaine is incompatible with silver and mercury salts, as well as basic substances. It also reduces the antimicrobial action of sulfonamides.^[2]

References

↑ ^1.0 ^1.1 Drugs.com: Minims Oxybuprocaine Hydrochloride 0.4%
↑ ^2.0 ^2.1 ^2.2 ^2.3 ^2.4 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
↑ PMID 17967152 (PMID 17967152)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

Template:Antipruritics

[Drugs.com-1] 1.0 ^1.1 Drugs.com: Minims Oxybuprocaine Hydrochloride 0.4%

[AustriaCodex-2] 2.0 ^2.1 ^2.2 ^2.3 ^2.4 Jasek, W, ed. (2007). Austria-Codex (in German) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.

[3] PMID 17967152 (PMID 17967152)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
-{{drugbox
+{{Drugbox
+| Watchedfields = changed
+| verifiedrevid = 462267348
 | IUPAC_name = 2-diethylaminoethyl 4-amino-3-butoxy-benzoate
-| image = Oxybuprocaine.svg
+| image =Oxybuprocaine.png
+<!--Clinical data-->
+| tradename = Novesin(e)
+| Drugs.com = {{drugs.com|international|oxybuprocaine}}
+| pregnancy_AU = D
+| legal_status =
+| routes_of_administration = Topical
+<!--Pharmacokinetic data-->
+| bioavailability =
+| protein_bound =
+| metabolism = [[Esterase]]s in blood plasma and liver
+| elimination_half-life =
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
 | CAS_number = 99-43-4
 | ATC_prefix = D04
 | ATC_suffix = AB03
-| ATC_supplemental = {{ATC|S01|HA02}}
+| ATC_supplemental =  {{ATC|S01|HA02}}
 | PubChem = 4633
-| DrugBank = APRD00817
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| C = 17 | H = 29 | Cl = 1 | N = 2 | O = 3
+ | DrugBank = DB00892
-| molecular_weight = 344.877 g/mol
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-| bioavailability =
+| ChemSpiderID = 4472
-| protein_bound =
+| UNII_Ref = {{fdacite|correct|FDA}}
-| metabolism =
+| UNII = AXQ0JYM303
-| elimination_half-life =
+| KEGG_Ref = {{keggcite|correct|kegg}}
-| pregnancy_category =
+| KEGG = D08319
-| legal_status =
+| ChEBI_Ref = {{ebicite|correct|EBI}}
-| routes_of_administration =
+| ChEBI = 309594
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 1200
+<!--Chemical data-->
+| C=17 | H=28 | N=2 | O=3
+| molecular_weight =  308.41 g/mol
+| smiles = O=C(OCCN(CC)CC)c1cc(OCCCC)c(cc1)N
+| InChI = 1/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
+| InChIKey = CMHHMUWAYWTMGS-UHFFFAOYAO
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = CMHHMUWAYWTMGS-UHFFFAOYSA-N
 }}
+__Notoc__
 {{SI}}
+{{CMG}}
+==Overview==
+'''Oxybuprocaine''' ([[International Nonproprietary Name|INN]]), also known as '''benoxinate''' or '''BNX''', is an ester-type [[local anesthetic]], which is used especially in [[ophthalmology]] and [[otolaryngology]]. Oxybuprocaine is sold by [[Novartis]] under the brand names '''Novesine''' or '''Novesin'''.
-==Overview==
+Safety for use in pregnancy and lactation has not been established.
-'''Oxybuprocaine''' is the name of a [[local anesthetic]], which is used especially in [[ophthalmology]] and [[otolaryngology]]. Oxybuprocaine is sold by [[Novartis]] under the brand names '''Novesine''' or '''Novesin'''.
-== Where oxybuprocaine is used specifically ==
+== Uses ==
+* In [[ophthalmology]] in order to numb the surface of the [[human eye|eye]] (the outermost layers of the [[cornea]] and [[conjunctiva]]) for the following purposes:<ref name="Drugs.com">Drugs.com: [http://www.drugs.com/uk/minims-oxybuprocaine-hydrochloride-0-4-917.html Minims Oxybuprocaine Hydrochloride 0.4%]</ref>
+** in order to perform a [[tonometry|contact/applanation tonometry]],
+** for small operations,
+** in order to remove small foreign objects from the uppermost layer of the cornea or conjunctiva;
+* in [[otolaryngology]] for numbing the [[mucous membrane]]s of the [[nostrils]] and [[pharynx]], for diagnostic purposes and small operations,<ref name="AustriaCodex">{{cite book|title=Austria-Codex|editor=Jasek, W|publisher=Österreichischer Apothekerverlag|location=Vienna|year=2007|edition=2007/2008|isbn=978-3-85200-181-4|language=German}}</ref>
+* for numbing the mucous membranes of [[bronchi]], for example in [[bronchoscopy]],<ref name="AustriaCodex" />
+* and the [[oesophagus]], for example in [[intubation]].<ref name="AustriaCodex" />
-* In [[ophthalmology]] in order to numb the surface of the [[eye]] (the outermost layers of the [[cornea]] and [[conjunctiva]]) for the following purposes:
+== Pharmacokinetics ==
-** In order to perform a [[tonometry|contact/applanation tonometry]].
+Anaesthesia starts with a latency of 30 to 50 seconds and lasts for about 10 to 30 minutes, depending on [[perfusion]]. The drug is metabolised by [[esterase]]s in blood plasma and liver.<ref name="AustriaCodex" />
-** In order to remove small foreign objects from the uppermost layer of the cornea or conjunctiva.
-* In [[otolaryngology]] for numbing the [[mucous membrane]]s of the [[nostrils]].
-== Topical anesthetics in general ==
+== Adverse effects ==
+When used excessively, oxybuprocaine like any other topical anesthetic used in the eye and on mucous membranes (like for example [[tetracaine]], [[proxymetacaine]] and [[proparacaine]]) can cause irritation, [[hypersensitivity]], [[anaphylaxis]], irreversible corneal damage and even complete destruction of the cornea.<ref name="Drugs.com" /><ref>{{cite pmid|17967152}}</ref> (Excessive use means several times a day during several days or even weeks.)
-Oxybuprocaine like any other topical anesthetic used in the eye (like for example [[tetracaine]], [[proxymetacaine]] and [[proparacaine]]) can cause irreversible corneal damage and even complete destruction of the cornea when used excessively (excessive use means several times a day during several days or even weeks).
+== Interactions ==
+Oxybuprocaine is incompatible with [[silver]] and [[mercury (element)|mercury]] salts, as well as [[Base (chemistry)|basic substances]]. It also reduces the antimicrobial action of [[sulfonamide (medicine)|sulfonamide]]s.<ref name="AustriaCodex" />
 ==See also==
 *[[Topical anesthetic]]
+==References==
+{{reflist|2}}
 {{Antipruritics}}
-[[Category:Eye stubs]]
+[[Category:Otorhinolaryngology]]
-[[Category:Otolaryngology]]
 [[Category:Local anesthetics]]
+[[Category:Benzoates]]
-[[de:Oxybuprocain]]
+[[Category:Anilines]]
-{{WikiDoc Sources}}
+[[Category:Drug]]
+[[Category:Phenol ethers]]